Celera Group
http://www.celera.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celera Group
Sanofi Secures World First Approval For Dupixent In COPD With EU Nod
The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.
Merck Takes Over Orion-Partnered Prostate Cancer Drug MK-5684
Deal Snapshot: Merck said it would pay potentially more than $1.6bn for an exclusive global license for opevesostat for metastatic castrate-resistant prostate cancer.
Apellis To Try Again After EMA Rejects Geographic Atrophy Drug
The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.
Quality Issues Star In US FDA Complete Response Letter Trio
Rocket Pharmaceuticals’ gene therapy Kresladi, Daiichi Sankyo/Merck’s patritumab deruxtecan, and AbbVie’s foscarbidopa/foslevodopa (ABBV-951) received CRLs because of manufacturing concerns.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice